▶ 調査レポート

多形性膠芽腫（GBM）再発治療の世界市場（～2026年）
• 英文タイトル：Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。多形性膠芽腫（GBM）再発治療の世界市場（～2026年） / Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2020-2026 / MRC2-11QY04474資料のイメージです。• レポートコード：MRC2-11QY04474
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、99ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア
• 販売価格（消費税別）
  Single User￥585,000 (USD3,900)▷ お問い合わせ
  Multi User￥877,500 (USD5,850)▷ お問い合わせ
  Enterprise License￥1,170,000 (USD7,800)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
当調査資料は多形性膠芽腫（GBM）再発治療のグローバル市場について調査・分析したレポートです。種類別（経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法）市場規模、用途別（病院、クリニック、外来外科センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別多形性膠芽腫（GBM）再発治療の競争状況、市場シェア
・世界の多形性膠芽腫（GBM）再発治療市場：種類別市場規模 2015年-2020年（経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法）
・世界の多形性膠芽腫（GBM）再発治療市場：種類別市場規模予測 2021年-2026年（経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法）
・世界の多形性膠芽腫（GBM）再発治療市場：用途別市場規模 2015年-2020年（病院、クリニック、外来外科センター）
・世界の多形性膠芽腫（GBM）再発治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来外科センター）
・北米の多形性膠芽腫（GBM）再発治療市場分析：米国、カナダ
・ヨーロッパの多形性膠芽腫（GBM）再発治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの多形性膠芽腫（GBM）再発治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の多形性膠芽腫（GBM）再発治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの多形性膠芽腫（GBM）再発治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Astrazeneca、Roche、GlaxoSmithKline、Merck、Pfizer、AngioChem、Vascular Biogeneics
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.
The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market.

Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market
The global Recurrent Glioblastoma Multiforme (GBM) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Scope and Market Size
Recurrent Glioblastoma Multiforme (GBM) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Recurrent Glioblastoma Multiforme (GBM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Astrazeneca
Roche
GlaxoSmithKline
Merck
Pfizer
AngioChem
Vascular Biogeneics
…

Market segment by Type, the product can be split into
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation Therapy
Chemotherapy
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
1.4 Market by Type
1.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Oral Medications
1.4.3 Temozolomide
1.4.4 Radiosensitizers
1.4.5 Nitrosoureas Drugs
1.4.6 Radiation Therapy
1.4.7 Chemotherapy
1.5 Market by Application
1.5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2015-2026)
2.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions
2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Recurrent Glioblastoma Multiforme (GBM) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Market Size
3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2015-2020)
3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio
3.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2019
3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
3.4 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
3.5 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)
5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in North America (2019-2020)
6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Europe (2019-2020)
7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
8.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in China (2019-2020)
8.3 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
8.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
9.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Japan (2019-2020)
9.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
9.4 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
10.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
11.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in India (2019-2020)
11.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
11.4 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020)
12.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Astrazeneca
13.1.1 Astrazeneca Company Details
13.1.2 Astrazeneca Business Overview
13.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020))
13.1.5 Astrazeneca Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.2.5 Roche Recent Development
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Details
13.3.2 GlaxoSmithKline Business Overview
13.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.3.5 GlaxoSmithKline Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 AngioChem
13.6.1 AngioChem Company Details
13.6.2 AngioChem Business Overview
13.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.6.5 AngioChem Recent Development
13.7 Vascular Biogeneics
13.7.1 Vascular Biogeneics Company Details
13.7.2 Vascular Biogeneics Business Overview
13.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
13.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)
13.7.5 Vascular Biogeneics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Recurrent Glioblastoma Multiforme (GBM) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
Table 3. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Oral Medications
Table 6. Key Players of Temozolomide
Table 7. Key Players of Radiosensitizers
Table 8. Key Players of Nitrosoureas Drugs
Table 9. Key Players of Radiation Therapy
Table 10. Key Players of Chemotherapy
Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2015-2020)
Table 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Strategy
Table 21. Main Points Interviewed from Key Recurrent Glioblastoma Multiforme (GBM) Treatment Players
Table 22. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2015-2020) (Million US$)
Table 23. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players (2015-2020)
Table 24. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2019)
Table 25. Global Recurrent Glioblastoma Multiforme (GBM) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
Table 28. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Type (2015-2020)
Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2021-2026)
Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2015-2020)
Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 35. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2021-2026)
Table 36. North America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 41. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 42. Europe Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 48. China Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 49. China Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 50. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 51. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 52. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 53. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 54. Japan Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 56. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 58. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 62. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 64. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 66. India Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 67. India Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 68. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 69. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 70. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 71. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020)
Table 74. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020)
Table 76. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020)
Table 78. Astrazeneca Company Details
Table 79. Astrazeneca Business Overview
Table 80. Astrazeneca Product
Table 81. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 82. Astrazeneca Recent Development
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Product
Table 86. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 87. Roche Recent Development
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Product
Table 91. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 92. GlaxoSmithKline Recent Development
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Product
Table 96. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 97. Merck Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Product
Table 101. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 102. Pfizer Recent Development
Table 103. AngioChem Company Details
Table 104. AngioChem Business Overview
Table 105. AngioChem Product
Table 106. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 107. AngioChem Recent Development
Table 108. Vascular Biogeneics Company Details
Table 109. Vascular Biogeneics Business Overview
Table 110. Vascular Biogeneics Product
Table 111. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$)
Table 112. Vascular Biogeneics Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Oral Medications Features
Figure 3. Temozolomide Features
Figure 4. Radiosensitizers Features
Figure 5. Nitrosoureas Drugs Features
Figure 6. Radiation Therapy Features
Figure 7. Chemotherapy Features
Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered
Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2019
Figure 18. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2019
Figure 20. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed

以下、関連資料のご紹介
  • 多形性膠芽腫（GBM）治療の世界市場（～2026年）
    Global Glioblastoma Multiforme Treatment (GBM) Market Size, Status and Forecast 2020-2026
    MRC2-11QY12056 2020年11月25日 92Pages
    当調査資料は多形性膠芽腫（GBM）治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、遺伝子治療、分子バイオテクノロジー）市場規模、用途別（ベバコズマブ、カルムスチン、テモゾロミド）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリ...
  • 多形性膠芽腫（GBM）治療薬の世界市場（～2026年）
    Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY12055 2020年11月25日 91Pages
    当調査資料は多形性膠芽腫（GBM）治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法、標的薬物療法、放射線療法）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...
  • 多形性膠芽腫治療薬の世界市場（～2026年）
    Global Glioblastoma Multiforme Therapeutics Market Insights and Forecast to 2026
    MRC2-11QY06842 2020年11月20日 115Pages
    当調査資料は多形性膠芽腫治療薬のグローバル市場について調査・分析したレポートです。種類別（テモゾロミド、ベバコズマブ、カルムスチン）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド...
  • 高カルシウム血症治療の世界市場（～2026年）
    Global Hypercalcemia Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY12275 2020年11月25日 95Pages
    当調査資料は高カルシウム血症治療のグローバル市場について調査・分析したレポートです。種類別（ビスフォスフォネート、糖質コルチコイド、カルシウム模倣薬）市場規模、用途別（軽度高カルシウム血症、中等度高カルシウム血症、重度高カルシウム血症）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フラン...
  • 交流電場腫瘍治療の世界市場（～2026年）
    Global Alternating Electric Field Tumor Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY13660 2020年11月30日 97Pages
    当調査資料は交流電場腫瘍治療のグローバル市場について調査・分析したレポートです。種類別（低周波、中周波）市場規模、用途別（病院、診療所、がん・放射線治療センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...
  • クラッベ病治療の世界市場（～2026年）
    Global Krabbe Disease Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY12467 2020年11月25日 94Pages
    当調査資料はクラッベ病治療のグローバル市場について調査・分析したレポートです。種類別（抗けいれん薬、筋弛緩薬、造血幹細胞移植、その他）市場規模、用途別（病院、ASC）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オー...
  • 軟骨無形成症治療の世界市場（～2026年）
    Global Achondroplasia Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY13545 2020年11月30日 95Pages
    当調査資料は軟骨無形成症治療のグローバル市場について調査・分析したレポートです。種類別（RBM-007、TA-46、B-701、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...
  • 静脈瘤治療の世界市場（～2026年）
    Global Varicose Vein Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY04979 2020年11月20日 96Pages
    当調査資料は静脈瘤治療のグローバル市場について調査・分析したレポートです。種類別（アブレーション装置、高周波アブレーション装置、レーザーアブレーション装置、静脈閉鎖製品）市場規模、用途別（静脈内アブレーション、注射硬化療法、外科的結紮/剥離）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、...
  • ニキビ治療の世界市場（～2026年）
    Global Acne Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY13550 2020年11月30日 97Pages
    当調査資料はニキビ治療のグローバル市場について調査・分析したレポートです。種類別（炎症性ニキビ、非炎症性ニキビ）市場規模、用途別（男性、女性）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米...
  • 酒さ治療の世界市場（～2026年）
    Global Rosacea Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY04537 2020年11月20日 98Pages
    当調査資料は酒さ治療のグローバル市場について調査・分析したレポートです。種類別（局所酒皶治療薬、経口酒皶治療薬）市場規模、用途別（病院、診療所、薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリ...
  • 多形性膠芽腫（GBM）治療の世界市場（～2026年）多形性膠芽腫（GBM）治療の世界市場（～2026年） Glioblastoma is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and …
  • 多形性膠芽腫（GBM）治療薬の世界市場（～2026年）多形性膠芽腫（GBM）治療薬の世界市場（～2026年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…
  • 多形性膠芽腫治療薬の世界市場（～2026年）多形性膠芽腫治療薬の世界市場（～2026年） Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or th…
  • 放射線皮膚炎治療の世界市場（～2026年）放射線皮膚炎治療の世界市場（～2026年） The pathophysiology of a radiation skin reaction is a combination of radiation injury and the subsequent inflammatory response and can occur at both the entrance and exit site of the irradiation. The major factor driving the radiation dermatitis treatment market is the increasing prevalence of cance…
  • 経口血糖降下薬（OAD）治療の世界市場（～2026年）経口血糖降下薬（OAD）治療の世界市場（～2026年） Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabet…